#Vascular Effects of NOVascular actions of NO include the following:    *      Direct vasodilation (flow dependent and receptor mediated)    *      Indirect vasodilation by inhibiting vasoconstrictor influences (e.g., inhibits angiotensin II and sympathetic vasoconstriction)    *      Anti-thrombotic effect - inhibits platelet adhesion to the vascular endothelium    *      Anti-inflammatory effect - inhibits leukocyte adhesion to vascular endothelium;
#(S1 (S (NP (NP (JJ Vascular) (NNS Effects)) (PP (IN of) (NP (JJ NOVascular) (NNS actions))) (PP (IN of) (NP (DT NO)))) (VP (VBP include) (NP (NP (DT the) (NN following)) (: :) (S (S (NP (NP (JJ *) (JJ Direct) (NN vasodilation)) (PRN (-LRB- -LRB-) (NP (NP (NN flow)) (ADJP (ADJP (JJ dependent)) (CC and) (ADJP (NN receptor) (JJ mediated)))) (-RRB- -RRB-))) (VP (VBZ *) (SBAR (S (NP (NP (JJ Indirect) (NN vasodilation)) (PP (IN by) (NP (VBG inhibiting) (NN vasoconstrictor) (NNS influences))) (PRN (-LRB- -LRB-) (NP (NNP e.g.)) (, ,) (NP (NNS inhibits)) (VP (VBG angiotensin) (NP (NNP II) (CC and) (JJ sympathetic) (NN vasoconstriction))) (-RRB- -RRB-))) (VP (VBZ *) (NP (JJ Anti-thrombotic) (NN effect))))))) (: -) (S (NP (NNS inhibits)) (VP (VBP platelet) (NP (NN adhesion)) (PP (TO to) (NP (NP (DT the) (JJ vascular) (NN endothelium)) (VP (VBG *) (NP (JJ Anti-inflammatory) (NN effect))))))) (: -) (S (NP (NNS inhibits)) (VP (VBP leukocyte) (NP (NN adhesion)) (PP (TO to) (NP (JJ vascular) (NN endothelium)))))))) (: ;)))
#Rule:Nouns
r1EffectsNNS
r1actionsNNS
r1followingNN
r1vasodilationNN
r1flowNN
r1receptorNN
r1vasodilationNN
r1vasoconstrictorNN
r1influencesNNS
r1e.g.LocationAnnotation
r1inhibitsNNS
r1IINNP
r1vasoconstrictionNN
r1effectNN
r1inhibitsNNS
r1adhesionNN
r1endotheliumNN
r1effectNN
r1inhibitsNNS
r1adhesionNN
r1endotheliumNN

#Rule:Verbs
r2includeVBP
r2*VBZ
r2inhibitingVBG
r2angiotensinVBG
r2*VBZ
r2plateletVBP
r2*VBG
r2leukocyteVBP

#Rule:Adjs
r4VascularJJ
r4NOVascularJJ
r4*JJ
r4DirectJJ
r4dependentJJ
r4mediatedJJ
r4IndirectJJ
r4sympatheticJJ
r4Anti-thromboticJJ
r4vascularJJ
r4Anti-inflammatoryJJ
r4vascularJJ

#Rule:Adj-Noun
r5VascularJJEffectsNNS
r5NOVascularJJactionsNNS
r5*JJvasodilationNN
r5DirectJJvasodilationNN
r5dependentJJflowNN
r5mediatedJJflowNN
r5IndirectJJvasodilationNN
r5inhibitingVBGinfluencesNNS
r5sympatheticJJvasoconstrictionNN
r5Anti-thromboticJJeffectNN
r5vascularJJendotheliumNN
r5Anti-inflammatoryJJeffectNN
r5vascularJJendotheliumNN

#Rule:N-HeadNoun
r8vasoconstrictorNNinfluencesNNS

#Rule:HeadNoun-V
r11EffectsNNSincludeVBP
r11vasodilationNN*VBZ
r11vasodilationNN*VBZ
r11inhibitsNNSplateletVBP
r11endotheliumNN*VBG
r11inhibitsNNSleukocyteVBP

#Rule:V-HeadNoun
r21includeVBPfollowingNN
r21angiotensinVBGvasoconstrictionNN
r21*VBZeffectNN
r21plateletVBPadhesionNN
r21*VBGeffectNN
r21leukocyteVBPadhesionNN

#Rule:PPinNP
r26EffectsNNSofINactionsNNS
r26EffectsNNSofINnoDT
r26vasodilationNNbyINinfluencesNNS

#Rule:PPinVP
r30plateletVBPtoTOendotheliumNN
r30leukocyteVBPtoTOendotheliumNN

# scavenges superoxide anion    *      Antiproliferative effect - inhibits smooth muscle hyperplasiaBecause of the above actions of NO, when its production is impaired or its bioavailability is reduced, the following can result:    *      Vasoconstriction (e.g., coronary vasospasm, elevated systemic vascular resistance, hypertension)    *      Thrombosis due to platelet aggregation and adhesion to vascular endothelium    *      Inflammation due to
#(S1 (S (NP (NNS scavenges)) (VP (VBP superoxide) (NP (NP (JJ anion) (NNP *) (NNP Antiproliferative) (NN effect)) (: -) (NP (NP (JJ inhibits) (JJ smooth) (NN muscle) (NN hyperplasiaBecause)) (PP (IN of) (NP (NP (DT the) (JJ above) (NNS actions)) (SBAR (IN of) (S (ADVP (RB NO)) (, ,) (SBAR (WHADVP (WRB when)) (S (S (NP (PRP$ its) (NN production)) (VP (AUX is) (ADJP (JJ impaired)))) (CC or) (S (NP (PRP$ its) (NN bioavailability)) (VP (AUX is) (VP (VBN reduced)))))) (, ,) (NP (DT the) (JJ following)) (VP (MD can) (VP (VB result)))))))) (: :) (NP (NP (NNP *) (NNP Vasoconstriction) (PRN (-LRB- -LRB-) (NP (NP (NN e.g.)) (, ,) (NP (JJ coronary) (NN vasospasm)) (, ,) (NP (JJ elevated) (JJ systemic) (JJ vascular) (NN resistance)) (, ,) (NP (NN hypertension))) (-RRB- -RRB-)) (NNP *) (NNPS Thrombosis)) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ platelet) (NN aggregation) (CC and) (NN adhesion)) (PP (TO to) (NP (NP (JJ vascular) (NN endothelium) (NNS *)) (ADJP (NNP Inflammation) (JJ due))))))))) (PP (TO to)))))
#Rule:Nouns
r1scavengesNNS
r1*NNP
r1AntiproliferativeNNP
r1effectNN
r1muscleNN
r1hyperplasiaBecauseNN
r1actionsNNS
r1productionNN
r1bioavailabilityNN
r1*NNP
r1Vasoconstriction (e.g.OrganizationAnnotation
r1coronary vasospasmPersonAnnotation
r1resistanceNN
r1hypertensionNN
r1*NNP
r1ThrombosisNNPS
r1aggregationNN
r1adhesionNN
r1endotheliumNN
r1*NNS
r1InflammationNNP

#Rule:Verbs
r2superoxideVBP
r2reducedVBN
r2resultVB

#Rule:Adjs
r4anionJJ
r4inhibitsJJ
r4smoothJJ
r4aboveJJ
r4impairedJJ
r4followingJJ
r4elevatedJJ
r4systemicJJ
r4vascularJJ
r4dueJJ
r4plateletJJ
r4vascularJJ
r4dueJJ

#Rule:Adj-Noun
r5anionJJeffectNN
r5inhibitsJJhyperplasiaBecauseNN
r5smoothJJhyperplasiaBecauseNN
r5aboveJJactionsNNS
r5dueJJThrombosisNNPS
r5elevatedJJresistanceNN
r5systemicJJresistanceNN
r5vascularJJresistanceNN
r5plateletJJaggregationNN
r5dueJJ*NNS
r5vascularJJ*NNS

#Rule:PRP-Noun
r6itsPRP$productionNN
r6itsPRP$bioavailabilityNN

#Rule:N-HeadNoun
r8AntiproliferativeNNPeffectNN
r8*NNPeffectNN
r8muscleNNhyperplasiaBecauseNN
r8*NNPThrombosisNNPS
r8endotheliumNN*NNS

#Rule:N-ApposN
r10Vasoconstriction (e.g.OrganizationAnnotationcoronary vasospasmPersonAnnotation

#Rule:HeadNoun-V
r11scavengesNNSsuperoxideVBP
r11followingJJresultVB
r11productionNNisAUX

#Rule:V-HeadNoun
r21superoxideVBPeffectNN

#Rule:V-HeadNoun(passive)
r23reducedVBNbioavailabilityNN

#Rule:V-ADJ
r25isAUXimpairedJJ

#Rule:PPinNP
r26hyperplasiaBecauseNNofINactionsNNS
r26aggregationNNtoTO*NNS

#Rule:PPinADJP
r37dueJJtoTOaggregationNN

#upregulation of leukocyte and endothelial adhesion molecules    *      Vascular hypertrophy and stenosisDiseases or Conditions Associated with Abnormal NO Production and Bioavailability    *      Hypertension    *      Obesity    *      Dyslipidemias (particularly hypercholesterolemia and hypertriglyceridemia)    *      Diabetes (both type I and II)    *      Heart failure    *      Atherosclerosis    *      Aging    *      Cigarette smoking
#(S1 (S (NP (NP (NN upregulation)) (PP (IN of) (NP (JJ leukocyte) (CC and) (JJ endothelial) (NN adhesion) (NNS molecules)))) (VP (VBD *) (NP (NP (NNP Vascular) (NN hypertrophy)) (CC and) (NP (NP (NNS stenosisDiseases) (CC or) (NNS Conditions)) (VP (VBN Associated) (PP (IN with) (NP (ADJP (JJ Abnormal) (NP (DT NO) (NNP Production) (CC and) (NNP Bioavailability) (NNP *) (NN Hypertension) (NNP *) (NNP Obesity) (NNP *) (NNP Dyslipidemias) (PRN (-LRB- -LRB-) (NP (RB particularly) (NN hypercholesterolemia) (CC and) (NNS hypertriglyceridemia)) (-RRB- -RRB-)) (NNP *) (NNP Diabetes) (PRN (-LRB- -LRB-) (NP (NP (NP (DT both) (NN type)) (NP (PRP I))) (CC and) (NP (NNP II))) (-RRB- -RRB-)) (NNP *) (NNP Heart) (NN failure) (NNP *) (NNP Atherosclerosis) (NNP *))) (VBG Aging) (NNP *) (NN Cigarette) (NN smoking)))))))))
#Rule:Nouns
r1upregulationNN
r1endothelial adhesionOrganizationAnnotation
r1moleculesNNS
r1VascularNNP
r1hypertrophyNN
r1stenosisDiseasesNNS
r1ConditionsNNS
r1Abnormal NO ProductionOrganizationAnnotation
r1BioavailabilityNNP
r1*NNP
r1HypertensionNN
r1*NNP
r1ObesityOrganizationAnnotation
r1*NNP
r1DyslipidemiasNNP
r1hypercholesterolemiaNN
r1hypertriglyceridemiaLocationAnnotation
r1*NNP
r1DiabetesNNP
r1typeNN
r1IINNP
r1*NNP
r1HeartNNP
r1failureNN
r1*NNP
r1AtherosclerosisNNP
r1*NNP
r1*NNP
r1Cigarette smokingOrganizationAnnotation

#Rule:Verbs
r2*VBD
r2associatedVBN
r2agingVBG

#Rule:Adjs
r4leukocyteOrganizationAnnotation

#Rule:Adj-Noun
r5leukocyteOrganizationAnnotationmoleculesNNS
r5endothelial adhesionOrganizationAnnotationmoleculesNNS
r5Abnormal NO ProductionOrganizationAnnotationCigarette smokingOrganizationAnnotation
r5agingVBGCigarette smokingOrganizationAnnotation

#Rule:N-HeadNoun
r8VascularNNPhypertrophyNN
r8*NNPCigarette smokingOrganizationAnnotation
r8AtherosclerosisNNP*NNP
r8*NNP*NNP
r8failureNN*NNP
r8HeartNNP*NNP

#Rule:HeadNoun-V
r11upregulationNN*VBD

#Rule:V-HeadNoun
r21*VBDhypertrophyNN

#Rule:V-HeadNoun(passive)
r24associatedVBNstenosisDiseasesNNS

#Rule:PPinNP
r26upregulationNNofINmoleculesNNS

#Rule:PPinVP
r32associatedVBNwithINCigarette smokingOrganizationAnnotation

@lemmas-left	NOVascular	bioavailability	sympathetic	influences	flow	its	production	vasoconstrictor	associate	stenosisDiseases	Bioavailability	superoxide	reduced	novascular	resistance	inhibit	Dyslipidemias	Vasoconstriction (e.g.	inflammation	heart	*	effects	Thrombosis	include	aggregation	conditions	Anti-inflammatory	angiotensin	hypertension	Hypertension	smooth	dependent	diabetes	influence	atherosclerosis	vasodilation	mediated	Cigarette smoking	Anti-thrombotic	molecule	Vascular	aging	direct	Direct	impaired	anti-thrombotic	Inflammation	Diabetes	inhibits	Indirect	inflammatory	adhesion	e.g.	actions	anion	scavenge	coronary vasospasm	hyperplasiabecause	antiproliferative	hyperplasiaBecause	type	age	Antiproliferative	action	be	II	Heart	reduce	failure	associated	Abnormal NO Production	due	molecules	stenosisdiseases	leukocyte	Effects	elevated	Atherosclerosis	hypertrophy	Conditions	result	scavenges	endothelium	endothelial adhesion	dyslipidemias	indirect	following	receptor	above	hypertriglyceridemia	vasoconstriction	Obesity	is	platelet	hypercholesterolemia	muscle	ii	upregulation	systemic	vascular	effect	inhibiting	thrombosis	
@lemmas-right	hypertrophy	result	coronary vasospasm	endothelium	hyperplasiabecause	no	hyperplasiaBecause	influence	bioavailability	influences	flow	vasodilation	production	stenosisDiseases	following	superoxide	Cigarette smoking	action	resistance	molecule	be	vasoconstriction	is	platelet	impaired	*	effects	Thrombosis	include	aggregation	effect	molecules	stenosisdiseases	adhesion	leukocyte	thrombosis	Effects	actions	
@lemmas-center	to	of	with	by	